Search All News
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
After skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States, and about one in eight men will be diagnosed with the disease during their lifetime.
Columbia researchers have identified a gene signature in localized prostate cancer that predicts the cancer’s odds of spreading and its response to a common treatment for advanced disease.
- September 20, 2018
Leaders in prostate cancer research and care will convene Sept. 22 for the inaugural NYC Prostate Cancer Summit, a patient-focused event co-hosted by CUIMC and NewYork-Presbyterian.
- May 4, 2017
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
- March 31, 2016
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
- May 12, 2014
Two genes together drive the most lethal forms of prostate cancer; could lead to diagnostic test and new treatments.
- October 31, 2013
Utilizing the latest techniques in molecular biology and genetics, the married team of Cory Abate-Shen and Michael Shen are tackling metastatic prostate cancer.
- September 11, 2013
A new genetic test may help determine which men with early prostate cancer can avoid surgery or other invasive treatment.
- April 23, 2013
A study from Columbia University’s Mailman School of Public Health is one of the first assessments of the link between obesity and precancerous abnormalities in biopsy tissue samples.
- August 9, 2010
Pilot Study by Columbia University Medical Center Urologic Surgeons Reports on Technology's Potential